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Abstract
Objectives: A P-value!0.05 is one metric used to evaluate the results of a randomized controlled trial (RCT). We wondered how often
statistically significant results in RCTs may be lost with small changes in the numbers of outcomes.
Study Design and Setting: A review of RCTs in high-impact medical journals that reported a statistically significant result for at least
one dichotomous or time-to-event outcome in the abstract. In the group with the smallest number of events, we changed the status of
patients without an event to an event until the P-value exceeded 0.05. We labeled this number the Fragility Index; smaller numbers indi-
cated a more fragile result.
Results: The 399 eligible trials had a median sample size of 682 patients (range: 15e112,604) and a median of 112 events (range:
8e5,142); 53% reported a P-value !0.01. The median Fragility Index was 8 (range: 0e109); 25% had a Fragility Index of 3 or less.
In 53% of trials, the Fragility Index was less than the number of patients lost to follow-up.
Conclusion: The statistically significant results of many RCTs hinge on small numbers of events. The Fragility Index complements the
P-value and helps identify less robust results.  2014 The Authors. Published by Elsevier Inc.
Keywords: Randomized controlled trials; Research methodology; Lost to follow-up
1. Introduction
In randomized controlled trials (RCTs), several factors
influence our belief in whether a treatment has an effect.
One influential factor is whether a hypothesis test demon-
strates statistical significance by rejecting the null hypoth-
esis at a particular threshold, most often a P-value less
than 0.05. Statistical significance implies that the observed
result, or a more extreme result, is unlikely to occur by
chance alone and that the groups are therefore likely to
truly differ.
The concept of a threshold P-value to determine stati-
stical significance aids our interpretation of trial results. It
allows us to distill the complexities of probability theory
into a threshold value that informs whether a true difference
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What is new
 Metrics exist, most notably p-values and 95% con-
fidence intervals, to help determine how likely
observed treatment effects are on the basis of
chance.
 A shift of only a few events in one group could
change typical hypothesis tests above the usual
thresholds considered statistically significant.
 The Fragility Index helps identify the number of
events required to change statistically significant
results to non-significant results.
 The Fragility Index demonstrate results from ran-
domized controlled trials in high impact journals
frequently hinge on three or fewer events.
likely exists. However, the use of threshold P-values has
received a great deal of criticism as an overly simple
concept to determine whether a treatment effect is likely
to truly exist. For example, readers may place a similar de-
gree of belief in results with similar P-values irrespective of
other factors such as the size of the trial or number of
events in the trial. Furthermore, readers may have very
different beliefs in the existence of a treatment effect on
the basis of very small differences in P-values when one
is above and one below the threshold value (eg,
P 5 0.051 and P 5 0.049). Despite these limitations, the
calculation, reporting, and interpretation of P-values and
the wide acceptance of a P ! 0.05 as significant persist.
One approach to better communicate the limitations of
P-value thresholds is to report an additional metric that
demonstrates how easily significance based on a threshold
P-value may be exceeded.
Consider a hypothetical example in which two RCTs at
low risk of bias evaluate investigational drugs compared
with placebo for the prevention of myocardial infarction.
In the first trial, 100 patients are randomized to receive drug
A and 100 patients to receive placebo. Fewer patients who
receive drug A suffer a myocardial infarction (one vs. nine
patients, P 5 0.02 by Fisher’s exact test). The second trial
randomizes 4,000 patients to receive drug B and 4,000
patients to receive placebo. Fewer patients who receive
drug B suffer a myocardial infarction (200 vs. 250 patients,
P 5 0.02).
As both trials were at low risk of bias and their results
demonstrated nearly the same P-value, one’s confidence
in a true effect might be similar. However, the results from
the first trial would be easily influenced by a small change
in the numbers of events. If only one more patient experi-
enced a myocardial infarction in the treatment group of
the first trial, the P-value would change to 0.06. Despite
the still impressive relative risk reduction of 78%, it would
no longer be considered statistically significant. In contrast,
adding one event to the treatment group in the second trial
would have no meaningful impact on either the P-value,
which would remain 0.02, or the point estimate of the rela-
tive risk reduction, which would remain 20%.
Knowing that statistical significance may be lost as a
result of a few additional events may reduce confidence that
a true treatment effect exists. The minimum number of pa-
tients whose status would have to change from a nonevent
to an event required to turn a statistically significant result
to a nonsignificant result could be used as an index of the
fragility of the result (ie, a Fragility Index), with smaller
numbers indicating a more fragile result. To explore the
concept of fragility, we reviewed RCTs published in high-
impact general medical journals and calculated the Fragility
Index of results reported to have a P ! 0.05.
2. Methods
We identified RCTs with a statistically significant result
for at least onedichotomous outcome in the abstract published
in high-impact general medical journals. We then calculated
the Fragility Index for each of these trial results and summa-
rized the Fragility Index as a function of trial characteristics.
2.1. Identification of trials
We used PubMed to identify RCTs published in the New
England Journal of Medicine, the Lancet, the Journal of
the American Medical Association, the Annals of Internal
Medicine, or the British Medical Journal using the random-
ized controlled trial MeSH term. We drew a convenience
sample determined by setting time limits of January 2004
to December 2010. Two reviewers independently screened
all identified abstracts. We included trials that (1) were two
parallel arm or two-by-two factorial design RCTs involving
humans (ie, cluster RCTs, crossover RCTs, andO2 parallel
arm designs were excluded), (2) allocated participants in a 1
to 1 ratio to treatment and control, and (3) in the abstract, re-
ported at least one dichotomous or time-to-event outcome as
significant (P! 0.05 or a 95% confidence interval (CI) that
excluded the null value) under a null hypothesis that no dif-
ference existed. Statistically significant results for a nonin-
feriority hypothesis were excluded.
2.2. Data
Two reviewers independently used standardized forms to
abstract data from each trial. Abstracted data elements
included details of the statistically significant outcome
(type of outcome, whether it was the primary study out-
come, use of adjustment, number of patients randomized
to each group, number of patients analyzed in each group,
and the number of patients who experienced an outcome in
each group), trial design (method of allocation, adequacy of
concealment, blinding, inclusion of all randomized patients
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in the analysis according to the group they were allocated
to), and the number of participants lost to follow-up. For
trials with more than one significant result reported in the
abstract, only the first reported result was considered. Dis-
agreements between reviewers were adjudicated by a third
reviewer.
2.3. Fragility Index calculation
The results of each trial were represented in a two-by-two
contingency table using the patient sample that the authors
used in the original analysis. For trials with a time-to-
event outcome, the number of events in each group for the
entire follow-up period was used as events to construct a
two-by-two table. The Fragility Index was calculated by
adding an event from the group with the smaller number
of events (and subtracting a nonevent from the same group
to keep the total number of patients constant) and recalculat-
ing the two-sidedP-value for Fisher’s exact test. Events were
iteratively added until the first time the calculated P-value
became equal to or greater than 0.05 (Fig. 1). The number
of additional events required to obtain a P-value 0.05
was considered the Fragility Index for that trial result. We
also performed a sensitivity analysis in which the Fragility
Index was calculated using the same two-by-two table as
the main analysis but was defined as the number of events
required to obtain a 95% CI for the relative risk that included
one, the null value.
2.4. Fragility Index by trial characteristics
We summarized the Fragility Index for the sampled
studies using descriptive statistics. We described the
Fragility Index of results based on whether they were pri-
mary outcomes, time-to-event outcomes, composite out-
comes, whether the original result was adjusted for
covariates, analysis was done by time-to-event methods,
whether all patients were included in the analysis of the pri-
mary outcome (ie, the intention-to-treat principle), whether
allocation was clearly concealed, the proportion of partici-
pants lost to follow-up, the magnitude of the original P-
value reported, sample size, and the total number of events
in the trial. We used linear regression models to evaluate as-
sociations between the Fragility Index (the dependent vari-
able) and trial characteristics (the independent variables).
For these models, we report the regression coefficients
and the 95% CIs calculated by 1,000 bootstrap samples.
We also determined the correlation between the Fragility
Index and trial sample size and the total number of out-
comes in the trial.
All calculations were performed using Stata MP, version
11 (StataCorp LP, College Station, TX, USA).
3. Results
We identified and reviewed the abstracts of 1,273 arti-
cles, of which 399 met our eligibility criteria (Appendix at
www.jclinepi.com). Table 1 summarizes the included trials’
characteristics. The median sample size was 682 patients
(range: 15e112,604), with a median of 112 events (range:
Fig. 1. Calculation of the Fragility Index in the scenario in which treatment A group has the fewest events. The smallest value of ‘‘f’’ that causes the
Fisher’s exact P-value to meet or exceed the 0.05 level is considered the Fragility Index. Higher values indicate less fragile results.
Table 1. Characteristics of included trials
Characteristic Number (n [ 399)
Journal, n (%)
New England Journal of Medicine 165 (41.3)
Lancet 112 (28.1)
Journal of the American Medical
Association
48 (12.0)
Annals of Internal Medicine 33 (8.3)
British Medical Journal 41 (10.3)
Sample size, median (minemax) 682 (15e112,604)
Number of outcome events, median
(minemax)
112 (8e5,142)




Included outcome, n (%)
Primary 263 (65.9)
Composite 132 (33.1)
Time to event 206 (51.6)
Adjusted 35 (8.8)
Abbreviations: min, minimum; max, maximum.
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8e5,142). The outcome evaluated was the primary outcome
in 65.9% of the trials. Fifty-three percent of RCTs reported
P-values!0.01. In 210 (52.6%) trials, all patients random-
ized were included in the analysis.
Fig. 2 reports the distribution of the Fragility Index for
all included trials. The median Fragility Index was 8
(25the75th percentile, 3e18; range, 0e808). Forty (10%)
trials became nonsignificant when we applied the Fisher’s
exact test to their contingency table and therefore had a
Fragility Index of zero. Of trials with a Fragility Index of
zero, 28 (70%) were originally analyzed by a time-to-
event analysis (of which, six were also adjusted for covari-
ates), 3 (7.5%) used adjusted analyses, and the remaining 9
(22.5%) used the chi-square test, CI-based approaches, or
imputed data for outcomes to determine statistical signifi-
cance. One-quarter of the trials (100) had a Fragility Index
less than or equal to 3. The sensitivity analysis using 95%
CIs did not differ materially from the main analysis and
demonstrated the same median and range of the Fragility
Index for this sample of trials.
Table 2 reports the Fragility Index by subgroups of trial
characteristics. All subgroups included trials with a Fragility
Index of zero. Furthermore, the 25th percentile of theFragility
Index was3 in all subgroups except for those with P-values
!0.01, the half with the largest number of events (ie,O112
events), and the quarter with the largest sample size (ie,
O2,522 participants). In linear regression, smaller reported
P-values, larger numbers of events, and larger sample size
were associatedwith less fragile results, and inadequate or un-
clear concealment was associated with more fragile results
(Table 3). The linear regression did not identify differences
in the Fragility Index on the basis of the outcome characteris-
tics assessed (ie, primary outcome, time-to-event outcome,
composite outcome). The Fragility Index was weakly corre-
lated to total sample size (r 5 0.28; P! 0.001) and moder-
ately correlated with total number of events (r 5 0.64;
P! 0.001; Fig. 3).
In the 306 trials that clearly reported loss to follow-up,
the median number of participants lost to follow-up was nine
(25the75th percentile, 2e39). The total number lost to
follow-up exceeded the Fragility Index in 162 (52.9%) trials.
When considering only the group in each trial with the
fewest number of events (ie, the group to which the Fragility
Index was added), the number of participants lost to follow-
up still exceeded the Fragility Index in 132 (43.1%) trials.
4. Discussion
The Fragility Index was 3 or less in 25% of dichotomous
outcomes from RCTs reported in high-impact general med-
ical journals. Examples of trials with fragile results (ie,
those with a small Fragility Index) were found across the
distribution of sample sizes and number of events. Further-
more, in more than half the RCTs, more participants were
lost to follow-up than would be required to make the result
nonsignificant based on the corresponding trial’s Fragility
Index. Reporting the Fragility Index for statistically signif-
icant results may allow clinicians to draw appropriate infer-
ences regarding their confidence in a putative treatment
effect.
The magnitude of the P-value or the distance of the lower
boundary of a CI from no effect, metrics that reflect potential
random error, influences our beliefs in trial results. In addi-
tion, statistical significance may also be influenced by meth-
odological limitations that increase systematic error (eg,
losses to follow-up or inadequate blinding) [1]. Integrating
Fig. 2. Distribution of Fragility Index for all trials. Inset graph limited to trials with a Fragility Index 40.
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these many factors is difficult. Work in cognitive psychology
demonstrated that even experts in probability are intuitively
poor in determining the relevance of these issues in the
experimental design [2]. Many clinicians are unlikely to
have substantial training in probability and statistics, and
intuitive interpretation of P-values and CIs is likely limited.
Treatment decisions often start with the decision of whether
a treatment effect is believed to exist. A simple metric, such
as the Fragility Index, may assist clinicians in determining
the confidence they should have in the result.
The importance of fragility is underscored by the num-
ber of RCTs that initially reported statistically significant
treatment effects but were later shown to be either ineffec-
tive (16%) or have effects that were substantially less than
initially reported (16%) [3]. The only parameter associated
with these findings is that the initial trial had a small sample
size. However, even trials generally regarded as large may
be fragile. Take, for example, the Leicester Intravenous
Magnesium Intervention Trial (LIMIT-2), which tested
the effect of intravenous magnesium on 28-day survival
in patients with suspected acute myocardial infarction [4].
The trial was, by most accounts, large with 2,316 patients
randomized, and it demonstrated a 24% relative risk reduc-
tion in mortality with a P-value of 0.04. Three years later, a
trial of more than 58,000 patients demonstrated no benefit,
and subsequent meta-analyses demonstrated that it was un-
likely any true benefit exists [5]. The Fragility Index of the
LIMIT-2 trial was 1. Had clinicians known this result
hinged on one event, they may have been hesitant to believe
and, therefore, act on it.
We are not the first group to suggest RCT results may be
fragile. Pocock suggested that statistically significant re-
sults that required only a single event to change to cross
the threshold of significance should be viewed with skepti-
cism [7]. In a 1990 publication, Feinstein suggested a Unit
Fragility Index that was computed by shifting one nonevent
to an event in one group and one event to a nonevent in the
second group [10]. Walter later expanded this concept and
concluded that more empirical evidence was needed [11].
The concepts developed by Feinstein and Walter are
similar to ours but more difficult to apply and interpret as
they do not report the absolute number of events required
to alter results (an intuitive metric) and they require deci-
sions about the magnitude of effect that constitutes clinical
significance.





All trials (n 5 399) 8 (3e18)
Outcome
Primary (n 5 263) 8 (3e21)
Not primary (n 5 136) 7 (2e14)
Time to event (n 5 206) 7.5 (3e17)
Not time to event (n 5 193) 9 (3e21)
Composite (n 5 132) 9 (3.5e22.5)
Not composite (n 5 367) 7 (2e15)
Analysis
Adjusted (n 5 35) 6 (1e15)
Not adjusted (n 5 364) 8 (3e19.5)
Intention to treat (n 5 210) 8 (3e17)
Not intention to treat (n 5 189) 7 (2e20)
Allocation concealment
Adequate (n 5 315) 8 (3e18)
Unclear or inadequate (n 5 84) 10 (3e18)
Lost to follow-up
1% (n 5 144) 8 (3e17)
O1e5% (n 5 88) 6 (3e13)
O5e10% (n 5 34) 8 (2e14)
O10% (n 5 40) 6 (2e19)
Not reported (n 5 93) 10 (4e33)
P-value
!0.05e0.01 (n 5 186) 3 (1e9)
!0.01e0.001 (n 5 168) 11 (5e21.5)
!0.001 (n 5 45) 26 (11e47)
Number of events
8e51 (n 5 100) 3 (1e7)
52e112 (n 5 100) 8 (3e15)
113e281 (n 5 100) 9 (5e21)
282e5,142 (n 5 99) 22 (6e52)
Sample size
15e286 (n 5 100) 4 (2e10)
287e682 (n 5 100) 6 (3e16)
683e2522 (n 5 100) 9 (2.5e18)
2523e112,604 (n 5 99) 14 (6e52)
Table 3. Association between trial characteristics and the Fragility
Index using linear regression
Characteristic b Coefficient (95% CI) P-value
Primary outcome 8.8 (23.2, 5.7) 0.23
Time-to-event outcome 0.3 (10.8, 10.1) 0.95
Composite outcome 5.7 (7.8, 19.2) 0.41
Adjusted analysis 2.7 (15.5, 10.1) 0.68
Intention-to-treat analysis 6.9 (18.0, 4.2) 0.22
Allocation concealment unclear
or inadequate
9.8 (17.6, 1.9) 0.02
Lost to follow-up
1% Referent
O1e5% 4.6 (7.5, 16.6) 0.46
O5e10% 3.0 (10.5, 4.6) 0.44
O10% 5.3 (12.7, 23.2) 0.57
Not reported 15.9 (2.7, 34.5) 0.09
Reported P-value
!0.05e0.01 Referent
!0.01e0.001 11.6 (4.0, 19.3) 0.003
!0.001 39.2 (4.9, 73.5) 0.03
Number of events
8e51 Referent
52e112 7.3 (4.5, 10.1) !0.001
113e281 10.0 (6.7, 13.3) !0.001
282e5,142 48.1 (27.7, 68.6) !0.001
Sample size
15e286 Referent
287e682 6.6 (2.7, 10.6) 0.001
683e2,522 9.5 (4.0, 15.0) 0.001
2,523e112,604 39.5 (19.6, 59.3) !0.001
Abbreviation: CI, confidence interval.
The b coefficient refers to the difference in the Fragility Index for
trials with compared with without the characteristic or compared with
the referent group.
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Reliance on P-values and their arbitrary thresholds to
interpret study results has been criticized for several de-
cades by statisticians and methodologists [6,7,8]. Despite
this, P-values continue to be commonly reported and play
an important part in the reporting and interpretation of
RCTs. Given the P-value is unlikely to be wholly replaced
by another statistic, addition of an equally simple metric
such as the Fragility Index may improve our understanding
of both trial results and P-values.
Others have suggested that the use of 95% CIs amelio-
rates the shortcomings of using P-values as a metric of sta-
tistical significance [9]. However, we believe that 95% CIs
are typically thought of as dichotomous entities in that they
either exclude the null value (signifying a statistically signif-
icant result) or they do not. The Fragility Index for P-values
is consistent with the number of events required to change
the bounds of a 95% CI from one that does not include
the null value to one that does. Also, if one considers the
example from the Introduction section in which a trial of
100 patients per group results in one vs. nine events, the rela-
tive risk reduction is 0.89 and the 95%CI is 0.14 to 0.99. The
larger trial of 4,000 patients per group and 200 compared
with 250 events results in a relative risk reduction of 0.20
and 95% CI of 0.04 to 0.33. Given the lower bound of the
95% CI is further from the null value in the small trial than
the large trial, one may be more confident a treatment effect
exists based on the results from the small trial. The Fragility
Index of only 1, however, would suggest that caution is
warranted in interpreting the results of the small trial. This
suggests that 95% CIs suffer from many of the same limita-
tions as P-values.
Yusuf et al. [12] suggested trials of at least 650 events
were required to be sufficiently confident that true effects
were identified in cardiovascular trials, and this was rein-
forced by simulation data [13]. Although this is appealingly
simple, it primarily addressed the probability that a treat-
ment effect that truly exists is missed by small trials (ie,
statistical power). Furthermore, it is based on the concept
of a risk in the control group of approximately 10% and
small to moderate effect sizes. The Fragility Index ad-
dresses the issue of treatment effects that are detected but
that may be unreliable. Both issues may, however, be
largely a function of trials too small to reliably determine
whether a treatment effect truly exists, and if it does,
whether the estimated effect is likely close to the true ef-
fect. Although the requirement for 650 events may be the
correct threshold for trials in many diseases/treatments,
there are scenarios in which large treatment effects may
require far less than 650 events for a robust assessment
of the treatment. Conversely, there are scenarios in which
there are more than 650 events, but the between-group dif-
ference is very small and therefore has a very small
Fragility Index suggesting even 650 events may be insuffi-
ciently robust. The Fragility Index is useful in both these
scenarios as shown in our data.
Although the Fragility Index can aid our understanding
of trial results, it has limitations. It applies only to 1 to 1
randomization and only to binary data. Outcomes measured
on continuous scales cannot, therefore, have a Fragility
Index computed, and the Fragility Index will not benefit
the interpretation of P-values in trials using continuous
scales as outcomes. However, most patient-important out-
comes are natural dichotomous (eg, death, stroke, myocar-
dial infarction), and important continuous outcomes are
frequently presented as dichotomies to aid interpretation.
The use of the Fragility Index in time-to-event analyses
may not always be appropriate. We found no material dif-
ference in the Fragility Index between time-to-event data
and frequency data, which is consistent with the concept
that most results are sensitive to the number of events in
each group rather than the timing of the events. However,
applying the Fragility Index to time-to-event data in which
the numbers of events in both groups are similar but there is
a clear difference in the timing of the events may be inap-
propriate and result in finding such trials inappropriately
fragile. We were also limited to two-group comparisons,
although our approach may be applied to pairs of groups
in studies with more than two groups. These limitations
aside, the Fragility Index will not identify all implausible
or false-positive RCT results. However, the Fragility Index
A
B
Fig. 3. Fragility Index by trial (A) sample size (all patients included in
analysis) and (B) total number of events.
627M. Walsh et al. / Journal of Clinical Epidemiology 67 (2014) 622e628
has the merit that it is very simple and may help integrate
concerns over smaller samples sizes and smaller numbers
of events that are not intuitive.
We conclude that the significant results of many RCTs
hinge on very few events. Reporting the number of events
required to make a statistically significant result nonsignif-
icant (ie, the Fragility Index) in RCTs may help readers
make more informed decisions about the confidence war-
ranted by RCT results.
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